Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13662924 | 0.95 | ALOX5 (0.31) | — | |
| SCHEMBL13662885 | 0.95 | ALOX5 (0.31) | — | |
| SCHEMBL13662884 | 0.92 | — | — | |
| SCHEMBL14364557 | 0.88 | — | — | |
| SCHEMBL12865413 | 0.85 | FFAR1 (0.33) | FFAR1FFAR4 | |
| SCHEMBL13662935 | 0.82 | — | — | |
| SCHEMBL12865409 | 0.79 | MGLL (0.34) | FFAR4 | |
| SCHEMBL13662941 | 0.71 | ATM (0.42) | — | |
| SCHEMBL4302103 | 0.70 | TUBB1 (0.33) | FFAR1FFAR4 | |
| SCHEMBL7893616 | 0.69 | ALOX5 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507669-B2 | Optically active dibenzazepine derivatives | NIPPON SODA CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20110034688-A1 | OPTICALLY ACTIVE DIBENZAZEPINE DERIVATIVES | NIPPON SODA CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034688-A1 | OPTICALLY ACTIVE DIBENZAZEPINE DERIVATIVES | DRD1, DRD4, DRD2 | FFAR1 2104/4885FFAR4 2081/4885 |
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | BCAT1, BCAT2, AADAT | FFAR1 1468/4885FFAR4 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.